-transparent.png){kind=logo}
The antitumor activity of berberine, berberrubine, and their derivatives against sarcoma-180 ascites was determined by the total packed cell volume method. Berbine and tetrahydroberberine derivatives had no antitumor activity, but berberrubine (9-demethylberberine) and the ester derivatives of berberrubine had a strong antitumor activity. ED90 of berberrubine, its acetate and benzoate, were 15, 23, and 44 mg/kg, respectively. The therapeutic indices (LD10/ED90 by the present method) of these compounds were as follows: Berberrubine hydrochloride, 6.7 approximately 9.4; 9-acetyl-9-demethylberberine (9-acetylberberrubine) chloride, 7.6 approximately 8.7; 9-benzoyl-9-demethylberberine (9-benzoylberberrubine) chloride, 3.4 approximately 4.9.
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
July 1982,
Journal of pharmacobio-dynamics,
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
August 1973,
Gan,
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
October 1973,
Gan,
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
January 1967,
Journal of medicinal chemistry,
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
May 2020,
Molecules (Basel, Switzerland),
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
October 1986,
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
August 2008,
Journal of medicinal chemistry,
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
September 1990,
Die Pharmazie,
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
July 2010,
Biotechnology letters,
A Hoshi, and
T Ikekawa, and
Y Ikeda, and
S Shirakawa, and
M Iigo
January 1992,
Cancer chemotherapy and pharmacology,
